Psilocybin’s effects may extend beyond the trip itself
A single dose of psilocybin may leave the brain changed for weeks, according to new research from UC San Francisco and Imperial College London. In a study of healthy volunteers with no prior psychedelic use, researchers found evidence that the compound triggered short-term changes in brain activity and likely anatomical changes that persisted for as long as a month after the experience.
The study, published in Nature Communications, adds to a growing body of work examining why psychedelic compounds have shown promise in treating depression, anxiety, and addiction. Rather than focusing only on the immediate subjective experience, the researchers tried to connect what was happening in the brain during the drug’s peak effects with how participants felt in the days and weeks that followed.
The central concept in the study is “entropy,” described here as the diversity or complexity of neural activity in the brain. The researchers found that higher doses of psilocybin increased entropy in the minutes and hours after participants took the drug. That mattered because the degree of this change was linked to how much insight or emotional self-awareness participants reported the next day. Those reported insights, in turn, forecast improvements in well-being one month later.
Why the researchers think insight matters
The work supports an idea that has become increasingly important in psychedelic science: the therapeutic value may not come from the chemical alone, but from the altered mental state it produces. Senior author Robin Carhart-Harris said the findings suggest that the psychedelic experience itself, and its brain correlates, are a key part of how psychedelic therapy may work.
That conclusion is notable because it pushes back against a simpler pharmaceutical model in which a drug’s benefits are assumed to be separable from the experience of taking it. In this study, the chain the researchers highlight runs from brain entropy to psychological insight to improved well-being. The implication is that the acute experience may be doing clinically relevant work.
The study was carried out in 28 healthy volunteers, a design choice that gave the team more freedom to use multiple monitoring techniques without the complications of an active psychiatric disorder. Participants underwent a range of brain measurements before dosing, during the peak experience, and again one month later. In the first part of the experiment, they received a 1 milligram dose that researchers treated as a placebo condition while recording brain activity with electroencephalography, or EEG.
Although the source summary only partially details the full protocol, it makes clear that the study used multiple imaging and measurement methods and that some observations were made during the peak psychedelic state. That combination is important because it lets researchers compare the immediate disruption of ordinary brain activity with the longer-lasting changes seen later.
What “higher entropy” could mean in practice
In neuroscience, entropy is often used as a way to describe how variable, flexible, or diverse patterns of brain activity are over time. In this case, higher entropy under psilocybin appears to reflect a loosening of ordinary patterns, potentially allowing new associations, emotional perspectives, or cognitive frameworks to emerge.
That interpretation fits the participants’ reports of increased insight and emotional self-awareness the day after the session. Instead of treating those reports as secondary or anecdotal, the researchers connected them directly to measurable brain signals. The more entropy increased, the more likely participants were to report meaningful insight, and the more likely they were to report improved well-being a month later.
For psychedelic medicine, that is a consequential result. It suggests future treatment models may need to preserve, guide, and interpret the subjective experience rather than minimize it. If the altered state is part of the mechanism, then set, setting, and follow-up support remain central rather than optional.
Promise, but not a clinical green light
The findings are intriguing, but they should not be read as proof that psilocybin is ready for broad medical use in every context. This was a small study in healthy volunteers, not a large clinical trial in patients with depression or addiction. The reported anatomical changes are described in the source as “likely,” which signals caution in how firmly those results should be interpreted.
Even so, the study helps sharpen a more precise scientific question. Instead of asking only whether psilocybin helps, researchers can ask which features of the experience predict benefit, how long those changes last, and whether similar brain signatures appear in patient populations. That could shape everything from dosing strategies to therapy design.
The study also arrives at a time when psychedelic research is moving from broad enthusiasm toward more mechanism-focused work. Regulators, clinicians, and investors increasingly want evidence not just that outcomes improve, but why. By tying short-term shifts in neural entropy to later self-reported gains in well-being, this research offers one of the clearer frameworks yet for explaining what happens between the dose and the lasting effect.
For now, the main takeaway is not that one psychedelic session is a universal fix. It is that a single dose, in a controlled setting, may temporarily reorganize how the brain functions in ways that outlast the acute experience. If those changes reliably support insight and well-being, they could help explain why psychedelic therapies continue to draw serious attention from mainstream neuroscience.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
